Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632929 | 0.95 | EGFR (0.44) | P2RX3P2RX2EGFRMEN1KMT2A | |
| SCHEMBL13499918 | 0.93 | EGFR (0.43) | EGFRLMNA | |
| SCHEMBL4718778 | 0.85 | EGFR (0.47) | P2RX3P2RX2EGFRMEN1KMT2A | |
| SCHEMBL3571140 | 0.83 | EGFR (0.43) | P2RX3P2RX2EGFRMEN1KMT2A | |
| SCHEMBL3631559 | 0.80 | EGFR (0.40) | P2RX3P2RX2EGFRLMNA | |
| SCHEMBL3632649 | 0.80 | CYP1A2 (0.45) | P2RX3P2RX2EGFRMEN1KMT2A | |
| SCHEMBL3582834 | 0.79 | PCSK9 (0.34) | P2RX3P2RX2 | |
| SCHEMBL4618634 | 0.79 | EGFR (0.49) | EGFRKMT2ALMNACYP2C19HSD17B10 | |
| SCHEMBL3627488 | 0.79 | EGFR (0.42) | P2RX3P2RX2EGFRMEN1KMT2A | |
| SCHEMBL3627509 | 0.76 | EGFR (0.43) | P2RX3P2RX2EGFRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | P2RX3 274/4885P2RX2 235/4885EGFR 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.